Welcome to LookChem.com Sign In|Join Free

CAS

  • or
methyl 4-bromo-3-methylthiophene-2-carboxylate is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

265652-38-8 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 265652-38-8 Structure
  • Basic information

    1. Product Name: methyl 4-bromo-3-methylthiophene-2-carboxylate
    2. Synonyms: methyl 4-bromo-3-methylthiophene-2-carboxylate;4-bromo-3-methyl-2-Thiophenecarboxylic acid methyl ester;4-Bromo-3-methyl-thiophene-2-carboxylic acid methyl ester
    3. CAS NO:265652-38-8
    4. Molecular Formula: C7H7BrO2S
    5. Molecular Weight: 235.09828
    6. EINECS: -0
    7. Product Categories: N/A
    8. Mol File: 265652-38-8.mol
  • Chemical Properties

    1. Melting Point: 61-61.5 °C
    2. Boiling Point: 263.3±35.0 °C(Predicted)
    3. Flash Point: N/A
    4. Appearance: /
    5. Density: 1.575±0.06 g/cm3(Predicted)
    6. Refractive Index: N/A
    7. Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
    8. Solubility: N/A
    9. CAS DataBase Reference: methyl 4-bromo-3-methylthiophene-2-carboxylate(CAS DataBase Reference)
    10. NIST Chemistry Reference: methyl 4-bromo-3-methylthiophene-2-carboxylate(265652-38-8)
    11. EPA Substance Registry System: methyl 4-bromo-3-methylthiophene-2-carboxylate(265652-38-8)
  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 265652-38-8(Hazardous Substances Data)

265652-38-8 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 265652-38-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,6,5,6,5 and 2 respectively; the second part has 2 digits, 3 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 265652-38:
(8*2)+(7*6)+(6*5)+(5*6)+(4*5)+(3*2)+(2*3)+(1*8)=158
158 % 10 = 8
So 265652-38-8 is a valid CAS Registry Number.

265652-38-8SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name 4-bromo-3-methyl-thiophene-2-carboxylic acid methyl ester

1.2 Other means of identification

Product number -
Other names 4-Brom-3-methyl-thiophen-2-carbonsaeure-methylester

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:265652-38-8 SDS

265652-38-8Relevant articles and documents

MALT1 MODULATORS AND USES THEREOF

-

Paragraph 00120; 00157; 00158, (2021/07/10)

Provided herein are compounds, compositions, and methods useful for modulating MALT1 and for treating related diseases, disorders, and conditions.

DNDI-6148: A Novel Benzoxaborole Preclinical Candidate for the Treatment of Visceral Leishmaniasis

Bello, Davide,Braillard, Stéphanie,Caljon, Guy,Carvalho, Sandra,Corpas-Lopez, Victoriano,Freund, Yvonne,Gilbert, Ian H.,Glossop, Paul A.,Jacobs, Robert T.,Lukac, Iva,Maes, Louis,Mowbray, Charles E.,Nare, Bakela,Pandi, Bharathi,Patterson, Stephen,Speake, Jason,Van Den Kerkhof, Magali,Wall, Richard J.,Whitlock, Gavin A.,Wyllie, Susan,Yardley, Vanessa,Zuccotto, Fabio

, p. 16159 - 16176 (2021/11/16)

Visceral leishmaniasis (VL) is a parasitic disease endemic across multiple regions of the world and is fatal if untreated. Current therapies are unsuitable, and there is an urgent need for safe, short-course, and low-cost oral treatments to combat this ne

METHODS OF TREATING NEURODEGENERATIVE DISEASES

-

Paragraph 0210, (2020/03/23)

Described herein are methods of treating or preventing an ASK1 or DYRK1A associated disease, disorder, or condition comprising administering to a subject in need thereof a dual inhibitor of ASK1 and DYRK1A; including administering pharmaceutically acceptable salts and solvates thereof.

ASK1 INHIBITOR COMPOUNDS AND USES THEREOF

-

Paragraph 0197, (2019/07/20)

Described herein are compounds, including pharmaceutically acceptable salts and solvates thereof, methods of making such compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat non-alcoholic steatohepatitis and other diseases characterized by dysfunctional tissue healing and fibrosis.

COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF

-

Paragraph 0469, (2018/07/04)

The present invention provides compounds that modulate protein function, to restore protein homeostasis, including cytokine, CK1α, GSPT1, aiolos, and/or ikaros activity, and cell-cell adhesion. The invention provides methods of modulating protein-mediated diseases, such as cytokine-mediated diseases, disorders, conditions, or responses. Compositions, including in combination with other cytokine and inflammatory mediators, are provided. Methods of treatment, amelioration, or prevention of diseases, disorders, or conditions associated with a protein, such as diseases, disorders, and conditions associated with cytokines, including inflammation, fibromyalgia, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, inflammatory bowel diseases, Crohn's disease, ulcerative colitis, uveitis, inflammatory lung diseases, chronic obstructive pulmonary disease, Alzheimer's disease, and cancer, are provided.

3-(PYRIDIN-3-YL)-ACRYLAMIDE AND N-(PYRIDIN-3-YL)-ACRYLAMIDE DERIVATIVES AND THEIR USE AS PAK OR NAMPT MODULATORS

-

Paragraph 00385, (2017/03/14)

The invention generally relates to cyclic compounds and, more particularly, to a compound represented by Structural Formula I: or a pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the multicyclic compounds. The invention also relates to a method for treating a disease or disorder selected from cancer (e.g., lymphoma, such as mantle cell lymphoma), a neurodegenerative disease, an inflammatory diseases or an immune system disease (e.g., a T- Cell mediated autoimmune diseases) in a subject in need thereof. The method comprises administering to a subject in need thereof a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof, or a composition comprising a compound of the invention, or a pharmaceutically acceptable salt thereof.

OXAZOLE AND ISOXAZOLE CRAC MODULATORS

-

Page/Page column 76, (2012/05/19)

The present invention relates to compounds of Formula (I) along with processes for their preparation that are useful for treating, preventing and/or managing the diseases, disorders, syndromes or conditions associated with the modulation of CRAC. The invention further relates to methods of treating, preventing managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of CRAC of Formula (I).

BENZOAZEPIN-OXY-ACETIC ACID DERIVATIVES AS PPAR-DELTA AGONISTS USED FOR THE INCREASE OF HDL-C, LOWER LDL-C AND LOWER CHOLESTEROL

-

Page/Page column 40, (2008/06/13)

The invention is directed to compounds of Formula (I) useful as PPAR agonists. Pharmaceutical compositions and methods of treating one or more conditions including, but not limited to, diabetes, nephropathy, neuropathy, retinopathy, polycystic ovary syndr

NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT

-

Page/Page column 24-25, (2008/06/13)

A method of treating atherosclerosis and related conditions using compounds of formula I: as well as pharmaceutically acceptable salts and solvates is disclosed. The compounds are useful for treating dyslipidemias, and in particular, reducing serum LDL, V

Novel thienopyridine compounds, and methods of use thereof

-

Page/Page column 32-33, (2008/06/13)

The present invention relates to novel compounds capable of modulating the stability and/or activity of hypoxia inducible factor (HIF).

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 265652-38-8